Regulation - Research, Johnson & Johnson


Current filters:

ResearchJohnson & Johnson

Popular Filters

Once-monthly Invega Sustenna reduces risk of relapse in schizoaffetive disorder

Once-monthly Invega Sustenna reduces risk of relapse in schizoaffetive disorder


US health care giant Johnson & Johnson subsidiary Janssen Pharmaceuticals has released positive results…

Invega SustennaJanssenJohnson & JohnsonNeurologicalPharmaceuticalRegulationResearch

Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth


At a meeting today with industry analysts, senior leaders from the Janssen pharmaceutical companies of…

FinancialJanssenJohnson & JohnsonPharmaceuticalRegulationResearch

Pharmacyclics and Janssen gain third FDA "Breakthrough" designation for ibrutinib; new Ph II data


Pharmacyclics (Nasdaq: PCYC) saw its shares gain 4.5% to $78.96 in early trading Monday, after it revealed…

ibrutinibJanssenJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulationResearch

US FDA grants "breakthrough" status for Janssen and Pharmacyclics ibrutinib


US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Research & Development, says that…

BiotechnologyibrutinibJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulationResearch

Strong results for Bayer's Xarelto in treating pulmonary blood clots


German drugs and crops sciences group Bayer (BAY: DE), and partner Janssen, part of US health care major…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalRegulationResearchRespiratory and PulmonaryXarelto

J&J’s Zytiga offers considerable added benefit in certain patients


US health care giant Johnson & Johnson’s Zytiga (abiraterone) was approved in Europe last fall for…

Johnson & JohnsonOncologyPharmaceuticalRegulationResearchZytiga

Back to top